The Latest Cardiac and Vascular News
Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life Additional Data Presented in Poster Session Shows Patients with Worsening Heart Failure and LVEF ≤30% Have Disproportionately High Risk of Heart Failure Hospitalization SOUTH SAN FRANCISCO, Calif., Oct. 02, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today […]
Presented at Key Scientific Society Meeting – Commonly Used Pressure Measures for Volume Assessment Proven Not Equivalent to BVA Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart validating the benefits of the […]
CARLSBAD, Calif. and BRISBANE, Australia, Sept. 30, 2022 /PRNewswire/ — ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to maximize patient health, today announced two poster presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, which is taking place Sept. 30 to Oct. […]
New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten SOUTH SAN FRANCISCO, Calif., Sept. 30, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today presented new data on the reduction and withdrawal of background standard of care medical therapy in patients treated […]
— Pediatric efficacy data for both patients show initial improvements across clinical, functional and biomarker endpoints with six to nine months of follow-up; positive results including protein expression obtained at three and six months consistent with adult cohorts at similar timeframe— — Results demonstrate sustained clinical benefit across all parameters in adult […]
The FNIH’s Accelerating Medicines Partnership® Heart Failure OXFORD, England, Sept. 29, 2022 /PRNewswire/ — Ultromics, a digital health technology company pioneering the development of transformative heart failure diagnostics, has joined as a full partner The Accelerating Medicines Partnership® Heart Failure (AMP® HF) including the National Institutes of Health (NIH) and the National Heart Lung and Blood Institute (NHLBI), managed […]
NORTH BETHESDA, Md., Sept. 29, 2022 /PRNewswire/ — The Foundation for the National Institutes of Health (FNIH) and the National Heart Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) are launching a new partnership to investigate the syndrome of heart failure with preserved ejection fraction (HFpEF). Developing precision […]
WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in early cardiogenic shock were published in the European Journal of Heart Failure (https://doi.org/10.1002/ejhf.2629). […]
CareDx Top-Tier Sponsor for Heart Failure Society of America Annual Scientific Meeting BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host a symposium to describe […]
MT. OLIVE, N.J. & CARLSBAD, Calif.–(BUSINESS WIRE)–Catheter Precision, Inc., a medical device and technology company focused on cardiac electrophysiology, announces that its lead product, VIVO™ (View Into Ventricular Onset), will be featured in presentations by three physicians working in the field of cardiac electrophysiology at the Sixth Annual Society of […]
